Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: Differential effects of Abciximab and Lamifiban

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 348-355

  Frojmovic, Mony ^a,b   Labarthe, Benoit ^a   Legrand, Chantal ^a,c  

^a INSERM   (France)

^b MCGILL UNIVERSITY   (Canada)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

IIb 3 antagonists; Aggregation; Platelet; Shear

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ARGININE; HIRUDIN; KETONE DERIVATIVE; LAMIFIBAN; PHENYLALANINE; ACETIC ACID DERIVATIVE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PADGEM PROTEIN; TYROSINE;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLOW MEASUREMENT; HUMAN; HUMAN TISSUE; LIGHT; NORMAL HUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; BLOOD; BLOOD CLOTTING PARAMETERS; BLOOD RHEOLOGY; BLOOD SAMPLING; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; METHODOLOGY; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ACETATES; ADENOSINE DIPHOSPHATE; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD PLATELETS; BLOOD SPECIMEN COLLECTION; FIBRINOGEN; HEMORHEOLOGY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 33644801483     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05782.x     Document Type: Article

References (33)

1. Artoni A. Li J. Mitchell B. Ruan J. Takagi J. Springer T.A. French D.L. Coller B.S. (2004) Integrin β3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin αIIbβ3 activation. Proceedings of the National Academy of Sciences of the United States of America, 101, 13114 13120.
2. Bihour C. Durrieu-Jaïs C. Macchi L. Poujol C. Coste P. Besse P. Nurden P. Nurden A.T. (1999) Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioslerosis Thrombosis and Vascular Biology, 19, 212 219.
3. Boersma E. Harrington R.A. Moliterno D.J. White H. Theroux P. Van de Werf F. de Torbol A. Armstrong P.W. Wallentin L.C. Wilcox R.G. Simes J. Califf R.M. Topol E.J. Simoons M.L. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359, 189 198.
4. Bonnefoy A. Hantgan R. Legrand C. Frojmovic M.M. (2001) A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor. Journal of Biological Chemistry, 276, 5605 5612.
5. Coller B.S. (1985) A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. Journal of Clinical Investigation, 76, 101 108.
6. Coller B.S. (2001) Anti-GPIIbIIIa drugs: current strategies and future directions. Thrombosis and Haemostasis, 86, 427 443.
7. Coller B.S. Peerschke E.I. Scudder L.E. Sullivan C.A. (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb/IIIa. Journal of Clinical Investigation, 72, 325 338.
8. Coller B.S. Folts J.D. Scudder L.E. Smith S.R. (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood, 68, 783 786.
9. D'Souza S.E. Haas T.A. Piotrowicz R.S. Byers-Ward V. McGrath D.E. Soule H.R. Cierniewski C. Plow E.F. Smith J.W. (1994) Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell, 79, 659 667.
10. Dickfeld T. Ruf A. Pogatsa-Murray G. Muller I. Engelmann B. Taubitz W. Fisher J. Meier O. Gawaz M. (2001) Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thrombosis Research, 101, 53 64.
11. Frojmovic M.M. (1998) Platelet aggregation in flow: differential roles for adhesive receptors and ligands. American Heart Journal, 135, S119 S131.
12. Frojmovic M.M. Kasirer-Friede A. Goldsmith H.L. Brown E.A. (1997) Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa. Thrombosis and Haemostasis, 77, 568 576.
13. Goto S. Ikeda Y. Saldivar E. Ruggeri Z.M. (1998) Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. Journal of Clinical Investigation, 101, 479 486.
14. Goto S. Tamura N. Ishida H. (2004) Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Journal of American College of Cardiologists, 44, 316 323.
15. Hanson S.R. Sakariassen K.S. (1998) Blood flow and antithrombotic drug effects. American Heart Journal, 135, S132 S145.
16. Harker L.A. (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. American Journal of Cardiologists, 60, 20B 28B.
17. Hu D.D. White C.A. Panzer-Knodle S. Page J.D. Nicholson N. Smith J.W. (1999) A new model of dual interacting ligand binding sites on αIIbβ3. Journal of Biological Chemistry, 274, 4633 4639.
18. Jurk K. Clemetson K.J. de Groot P.G. Brodde M.F. Steiner M. Savion N. Varon D. Sixma J.J. Van Aken H. Kehrel B.E. (2003) Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB Journal, 17, 1490 1492.
19. Kandzari D.E. Hasselblad V. Tcheng J.E. Stone G.W. Califf R.M. Kastrati A. Newman F.J. Brener S.J. Montalescot G. Kong D.F. Harrington R.A. (2004) Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. American Heart Journal, 147, 457 462.
20. Kasirer-Friede A. Legrand C. Frojmovic M.M. (2001) Complementary roles for fibrin(ogen), thrombospondin and vWF in mediating shear-dependent aggregation of platelets stimulated at threshold thrombin concentrations. Thrombosis and Haemostasis, 86, 653 659.
21. Kleiman N.S. Raizner A.E. Jordan R. Wang A.L. Norton D. Mace K.F. Joshi A. Coller B.S. Weisman H.F. (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Journal of American College of Cardiologists, 26, 1665 1671.
22. Lagadec P. Dejoux O. Ticchioni M. Cottrez F. Johansen M. Brown E.J. Bernard A. (2003) Involvement of a CD47-dependent pathway in platelet adhesion on inflamed vascular endothelium under flow. Blood, 101, 4836 4843.
23. Marciniak Jr., S.J. Jordan R.E. Mascelli M.A. (2001) Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thrombosis and Haemostasis, 85, 539 543.
24. Marciniak Jr., S.J. Mascelli M.A. Furman M.I. Michelson A.D. Jakubowski J.A. Jordan R.E. Marchese P.J. Frelinger A.L. (2002) An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thrombosis and Haemostasis, 87, 1020 1025.
25. Mousa S.A. Bozarth J.M. Forsythe M.S. Slee A. (2000) Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. Cardiovascular Research, 47, 819 826.
26. Nieswandt B. Watson S. (2003) Platelet-collagen interaction: is GPVI the central receptor Blood, 102, 449 461.
27. 2+ on GP IIb-IIIa interactions with Integrilin: enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation, 96, 1488 1494.
28. Ruggeri Z.M. (2002) Platelets in atherothrombosis. Nature Medicine, 8, 1227 1234.
29. Savage B. Ulmus-Jacobs F. Ruggeri Z.M. (1998) Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell, 94, 657 666.
30. Scarborough R.M. Naughton M.A. Teng W. Rose S.W. Phillips D.R. Nannizzi L. Arfsten A. Campbell A.M. Charo I.F. (1993) Design of potent and specific antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. Journal of Biological Chemistry, 268, 1066 1073.
31. Turner N.A. Moake J.L. McIntire L.V. (2001) Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow. Blood, 98, 3340 3345.
32. Xia Z. Frojmovic M.M. (1994) Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophysical Journal, 66, 2190 2201.
33. Xia Z. Wong T. Liu Q. Kasirer-Friede A. Brown E. Frojmovic M.M. (1996) Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. British Journal of Haematology, 93, 204 214.